| Pancreatic cancer D Li, K Xie, R Wolff, JL Abbruzzese The Lancet 363 (9414), 1049-1057, 2004 | 2740 | 2004 |
| STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018 | 1282 | 2018 |
| Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial HA Tawbi, M Burgess, V Bolejack, BA Van Tine, SM Schuetze, J Hu, ... The Lancet Oncology 18 (11), 1493-1501, 2017 | 1139 | 2017 |
| Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic … F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ... Cancer discovery 5 (8), 860-877, 2015 | 797 | 2015 |
| Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5 XP Yang, K Ghoreschi, SM Steward-Tharp, J Rodriguez-Canales, J Zhu, ... Nature immunology 12 (3), 247-254, 2011 | 695 | 2011 |
| Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma FF Lang, C Conrad, C Gomez-Manzano, WKA Yung, R Sawaya, ... Journal of clinical oncology 36 (14), 1419-1427, 2018 | 595 | 2018 |
| A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition MP Mak, P Tong, L Diao, RJ Cardnell, DL Gibbons, WN William, ... Clinical Cancer Research 22 (3), 609-620, 2016 | 437 | 2016 |
| Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16–related cancer: a phase 2 clinical trial E Massarelli, W William, F Johnson, M Kies, R Ferrarotto, M Guo, L Feng, ... JAMA oncology 5 (1), 67-73, 2019 | 426 | 2019 |
| CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade L Chen, L Diao, Y Yang, X Yi, BL Rodriguez, Y Li, PA Villalobos, ... Cancer discovery 8 (9), 1156-1175, 2018 | 382 | 2018 |
| CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells J Kim, Z Hu, L Cai, K Li, E Choi, B Faubert, D Bezwada, ... Nature 546 (7656), 168-172, 2017 | 270 | 2017 |
| Fatty acid oxidation mediated by Acyl-CoA synthetase long chain 3 is required for mutant KRAS lung tumorigenesis MS Padanad, G Konstantinidou, N Venkateswaran, M Melegari, S Rindhe, ... Cell reports 16 (6), 1614-1628, 2016 | 264 | 2016 |
| Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues ER Parra, N Uraoka, M Jiang, P Cook, D Gibbons, MA Forget, ... Scientific reports 7 (1), 13380, 2017 | 260 | 2017 |
| Diagnosis and molecular classification of lung cancer J Rodriguez-Canales, E Parra-Cuentas, II Wistuba Lung Cancer: Treatment and Research, 25-46, 2016 | 260 | 2016 |
| A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors I Petrini, PS Meltzer, IK Kim, M Lucchi, KS Park, G Fontanini, J Gao, ... Nature genetics 46 (8), 844-849, 2014 | 258 | 2014 |
| The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation JM Taube, G Akturk, M Angelo, EL Engle, S Gnjatic, S Greenbaum, ... Journal for immunotherapy of cancer 8 (1), 2020 | 200 | 2020 |
| XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer J Kim, E McMillan, HS Kim, N Venkateswaran, G Makkar, ... Nature 538 (7623), 114-117, 2016 | 200 | 2016 |
| ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis DH Peng, C Ungewiss, P Tong, LA Byers, J Wang, JR Canales, ... Oncogene 36 (14), 1925-1938, 2017 | 193 | 2017 |
| Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up H Kadara, M Choi, J Zhang, ER Parra, J Rodriguez-Canales, SG Gaffney, ... Annals of Oncology 28 (1), 75-82, 2017 | 193 | 2017 |
| Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases H Shao, L Xi, M Raffeld, AL Feldman, RP Ketterling, R Knudson, ... Modern Pathology 24 (11), 1421-1432, 2011 | 192 | 2011 |
| Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome SC Tripathi, HL Peters, A Taguchi, H Katayama, H Wang, A Momin, ... Proceedings of the National Academy of Sciences 113 (11), E1555-E1564, 2016 | 188 | 2016 |
Edwin Roger Parra CuentasDr. Faculdade de Medicina da Universidade de São Paulo在 usp.br 的电子邮件经过验证
